不同剂量瑞舒伐他汀用于急诊PCI患者的疗效及 对Lp-PLA2、IL-6、TNF-α的影响.

Objective: To study Curative efficacy of different doses of rosuvastatin in treatment of primary percutaneous coronary intervention(PCI) and its effects on lipoprotein associated phospholipase A2(Lp-PLA2), interleukin(IL)-6 and tumor necrosis factor(TNF) -αlevels levels. Methods: 120 patients of acute coronary syndromes(ACS) who received therapy from February 2014 to February 2016 in our hospital were selected, all emergency departments were PCI. According to randomnumber table, those patients were divided into the A group(n=40), B group(n=48) and C group(n=40). The three groups received routine treatment after PCI, on this basis, A group rosuvastatin dose of 10 mg, A group rosuvastatin dose of 20 mg, C group rosuvastatin dose of 40 mg, 1 times /d, take before going to bed, continuous medication 7 d. The changes of heart rate (HR), heart function and Lp-PLA2, IL-6 and TNF-αthe three groups were compared before and after treatment, the incidence of adverse cardiovascular events was recorded for a year following up. Results: After treatment, the HR, cardiac function index, Lp-PLA2, IL-6, TNF-αin three groups were significantly improved compared with before treatment(P＜ 0.05); in the HR, C group < B group < A group, there were significant differences between groups(P＜0.05); in the left ventricular end diastolic diameter (LVEDD), left ventricular end systolic diameter (LVESD), left ventricular end diastolic volume (LVEDV), left ventricular end systolic volume (LVESV), left ventricular ejection fraction (LVEF) results, the improvement degree ofC group was better than that ofB group and A group, there were significant differences between groups(P＜0.05); in the Lp-PLA2, IL-6 and TNF-α, C group < B group <A group, there were significant differences between groups (P＜0.05); follow up showed, the restenosis rate in the C group was significantly lower than that of the B group andA group, the myocardial infarction in the A group was significantly higher than that of the C group(P＜0.05), there was no significant difference in cardiogenic shock and mortality between the three groups(P＞0.05). Concluvion: 40mg of rosuvastatin is well for after primary PCI, it's can improve heart function, and it's intrinsic mechanism may be related to the reduction of Lp-PLA2, IL-6 and TNF-αexpression. [ABSTRACT FROM AUTHOR]